title: Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients.
authors.affiliation: Kirby Institute, UNSW, Sydney, Australia. m.danta@unsw.edu.au.
authors.forename: D
authors.initials: D
authors.lastname: Bradshaw
authors.forename: M
authors.initials: M
authors.lastname: Danta
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; C413685:entecavir; D006147:Guanine; D000068698:Tenofovir; D000225:Adenine